里程碑！FDA首次批准AI工具助力新药研发

Med新声12-09

12月8日路透社消息，FDA宣布，已正式批准首款人工智能（AI）工具用于药物临床试验中重度脂肪肝疾病的评估工作。该工具名为AIM-NASH，将面向所有相关药物研发项目开放使用，为代谢相关脂肪性肝炎（MASH）的新药研发按下“加速键”。作为一款云端系统，AIM-NASH的核心功能是通过AI算法分析肝组织图像，精准识别脂肪堆积、炎症反应、组织瘢痕等疾病关键特征，并依据标准评分体系生成评估结果，最终由...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590632000?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-09 14:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590632000","market":"us","top_or_hot":-1,"title":"里程碑！FDA首次批准AI工具助力新药研发","media":"Med新声","content":"<div>\n<p>12月8日路透社消息，FDA宣布，已正式批准首款人工智能（AI）工具用于药物临床试验中重度脂肪肝疾病的评估工作。该工具名为AIM-NASH，将面向所有相关药物研发项目开放使用，为代谢相关脂肪性肝炎（MASH）的新药研发按下“加速键”。作为一款云端系统，AIM-NASH的核心功能是通过AI算法分析肝组织图像，精准识别脂肪堆积、炎症反应、组织瘢痕等疾病关键特征，并依据标准评分体系生成评估结果，最终由...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209145228a72cb8ee&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>里程碑！FDA首次批准AI工具助力新药研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n里程碑！FDA首次批准AI工具助力新药研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-09 14:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209145228a72cb8ee&s=b><strong>Med新声</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月8日路透社消息，FDA宣布，已正式批准首款人工智能（AI）工具用于药物临床试验中重度脂肪肝疾病的评估工作。该工具名为AIM-NASH，将面向所有相关药物研发项目开放使用，为代谢相关脂肪性肝炎（MASH）的新药研发按下“加速键”。作为一款云端系统，AIM-NASH的核心功能是通过AI算法分析肝组织图像，精准识别脂肪堆积、炎症反应、组织瘢痕等疾病关键特征，并依据标准评分体系生成评估结果，最终由...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209145228a72cb8ee&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIM","symbol_name":"AIM ImmunoTech Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209145228a72cb8ee&s=b","article_id":"2590632000","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209145228a72cb8ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590632000","pubTimestamp":1765260981,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月8日路透社消息，FDA宣布，已正式批准首款人工智能工具用于药物临床试验中重度脂肪肝疾病的评估工作。据FDA介绍，目前MASH药物临床试验中，肝活检样本需经多名专家独立评审，不仅流程繁琐缓慢，且评审结果易出现不一致性。此次FDA的资格认定，基于多项研究证实：AIM-NASH辅助下的评估结果，与单个专家的独立评审水平相当，其准确性和可靠性得到充分验证。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AIM":"AIM ImmunoTech Inc.","BK4557":"大麻股","BK4139":"生物科技"},"translate_title":"Milestone! FDA approves AI tools for the first time to help new drug development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":0.9},"content_text":"12月8日路透社消息，FDA宣布，已正式批准首款人工智能（AI）工具用于药物临床试验中重度脂肪肝疾病的评估工作。该工具名为AIM-NASH，将面向所有相关药物研发项目开放使用，为代谢相关脂肪性肝炎（MASH）的新药研发按下“加速键”。作为一款云端系统，AIM-NASH的核心功能是通过AI算法分析肝组织图像，精准识别脂肪堆积、炎症反应、组织瘢痕等疾病关键特征，并依据标准评分体系生成评估结果，最终由医生进行最终解读。据FDA介绍，目前MASH药物临床试验中，肝活检样本需经多名专家独立评审，不仅流程繁琐缓慢，且评审结果易出现不一致性。而AIM-NASH能够实现评估标准化，显著缩短新药研发周期、降低资源消耗，助力新疗法更快惠及患者。此次FDA的资格认定，基于多项研究证实：AIM-NASH辅助下的评估结果，与单个专家的独立评审水平相当，其准确性和可靠性得到充分验证。行业专家指出，AI技术在药物研发领域的应用正加速普及，预计未来3-5年内，这类技术有望将药物研发的时间和成本至少降低一半，为更多疑难疾病的治疗突破带来新可能。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590632000","isCrawlerRequest":true}